Where does Medivance Incorporated rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Medivance Incorporated ranks #16,984 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Medivance Incorporated hold?

Medivance Incorporated holds 17 US utility patents granted between 2016 and 2025, spanning 4 technology areas.

What is Medivance Incorporated's Innovation Score?

Medivance Incorporated has an Innovation Score of 41.6 out of 100 (top 33% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Medivance Incorporated's patent grant rate increasing or decreasing?

Medivance Incorporated's recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Medivance Incorporated's patents?

Medivance Incorporated's patents average 24.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Medivance Incorporated patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Medivance Incorporated

Q: What technology areas does Medivance Incorporated focus on?

Medivance Incorporated's top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 17 patents, ranking #378 of 3,082 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 17 granted patents across 4 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Medivance ranks #16,984 of 49,997 tracked US assignees by granted-patent volume, with 17 patents across 4 technology areas.

#16,984
of 49,997 US assignees by volume: Top 33%
by Innovation Score (41.6/100): 24.2
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R16984 · US Corporation #16,984 · 17 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-MICRO 17 grants
MID-PACK #16,984/49,997
PHOTO-FINISH Malvern Instruments
CPC-NARROW A61F · 4 areas
INNOV-PAR 41.6/100
CLAIMS-DENSE 24.2 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Malvern Instruments Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Medivance’s 41.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.0 pts (24%) Velocity 10.0 pts (24%) Breadth 7.1 pts (17%) Claim depth 14.5 pts (35%)

Qualcomm Incorporated · highest

85
Medivance Incorporated · this assignee

42
3D Lighting… · lowest

7

What this shows Medivance's Innovation Score is 41.6/100 (top 33% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Medivance?

Each dot is one of Medivance’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Medivance’s own 24.2 claims/patent is ABOVE the 17.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Medivance vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Medivance's grants concentrate

Medivance Incorporated is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2017 (4 grants) versus a trough of 1 in 2016. By volume, Medivance sits between Malvern Instruments Limited and MessageOne, LLC.

Medivance's three-year grant acceleration

Medivance Incorporated shows 6 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Malvern Instrumen…

17
Marco Systemanaly…

17
Marotta Controls

17
Medic

17
Medrobotics

17
Medway Plastics

17
Memray

17
Messageone

17
Medivance Incorpo… ◀

17

What this shows Medivance holds 17 patents at rank #17,000, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Medivance

By rank, the assignees closest to #17,000 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Medivance's primary technology class.

Medivance's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 33% higher than 67% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Medivance Incorporated patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	5.9%
2017	4	23.5%
2018	1	5.9%
2019	2	11.8%
2020	2	11.8%
2022	2	11.8%
2023	3	17.6%
2024	1	5.9%
2025partial year	1	5.9%

Which technologies does Medivance Incorporated patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 17

A61B - DIAGNOSIS; SURGERY; Identification 8

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 3

G01F - Measuring Volume, Volume Flow, Mass Flow OR Liquid LEVEL; Metering BY Volume 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Medivance Incorporated's patent record in context - here's where to go next.

Medivance Incorporated's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 100% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #16,984 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Medivance Incorporated against Malvern Instruments Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.